I-Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC) API

Incazelo emfushane:

Igama Lekhemikhali: Ibrutinib

I-CAS: 936563-96-1

Ubumsulwa: >99.5% (HPLC)

Ukubukeka: Okumhlophe kuya Kokumhlophe Kwe-Crystal Powder

I-Ibrutinib iyi-BTK inhibitor esetshenziselwa ukwelapha i-Chronic Lymphocytic Leukemia (CLL) kanye ne-Mantle Cell Lymphoma (MCL)

Thintana: UDkt. Alvin Huang

Iselula/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali	Ibrutinib
Omqondofana	1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- eyodwa;PCI-32765
Inombolo ye-CAS	936563-96-1
Isimo Sesitoko	Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula	I-C25H24N6O2
Isisindo samangqamuzana	440.50
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	I-Crystal Powder emhlophe ukuya kokumhlophe
Ukuhlonza	I-IR;I-HPLC
Ukulahlekelwa Ekumisweni	<0.50%
Izinsalela ekushiseni	≤0.10%
Izinsimbi Ezisindayo (njenge-Pb)	≤20ppm
Noma Ikuphi Ukungcola Okukodwa	≤0.20%
Ukungcola Okuphelele	<0.50%
Ukuhlanzeka / Indlela Yokuhlaziya	>99.5% (HPLC)
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	I-API

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.

Izinzuzo:

I-FAQ:

Isicelo:

I-Ibrutinib (i-CAS: 936563-96-1) iyi-inhibitor ye-Bruton tyrosine kinase (BTK) yokwelashwa kwe-lymphocytic leukemia engapheli (CLL) kanye ne-mantle cell lymphoma (MCL).Kokubili i-MCL ne-CLL kungokwe-B-cell non-Hodgkin's lymphoma, ephikisayo futhi ejwayele ukuphinda ibuyele emuva.I-chemoimmunotherapy evame ukusetshenziswa ayiqondisiwe, futhi ukusabela okubi kwebanga lesi-3 noma le-4 kuvame ukwenzeka.I-Ibrutinib ingahlangana ne-BTK, edingekayo ekwakhekeni, ukuhlukaniswa, ukuxhumana nokusinda kwama-lymphocyte e-B, futhi ivimbele ngokungenakuphikiswa umsebenzi we-BTK, ivimbele ngempumelelo ukwanda nokusinda kwamaseli wesimila.Ngaphezu kwalokho, imuncwa ngokushesha ngemva kokuphathwa ngomlomo, ukugcwala okukhulu kwe-plasma kufinyelelwa ku-1 ~ 2h, futhi ukusabela okungathandeki kubanga 1 noma 2, okuzoba yindlela entsha yokwelashwa kwe-CLL ne-MCL.Ngomhla ziyi-13 kuNovemba, 2013, i-FDA yase-US izosheshisa inkampani egunyaziwe kaJohnson & Johnson kanye ne-United States Imbruvica (igama elivamile: Ibrutinib) yokwelashwa kwe-mantle cell lymphoma (MCL).I-Ibrutinib, yanikezwa isikhundla sokwelapha ngempumelelo yi-FDA ngoFebhuwari 2013 futhi yagunyazwa i-MCL ngoNovemba 13, 2013 kanye ne-CLL ngoFebhuwari 12, 2014, ngokulandelana.